A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation.

Trial Profile

A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Beta-thalassaemia; Iron overload
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Dec 2015 Interim results (n=26) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top